ADAR1 Capital Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001940272

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q4 2025 · 256 positions · Total reported value $1.29B · Top-10 concentration 47.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 47.5% · 33 new · 62 cut · 48 exited

Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -7.0% · vs SPY -9.1% · Prev Value $1.81B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.7% · vs SPY -5.9% · Latest Value $1.82B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2025 13F filing, ADAR1 Capital Management, LLC disclosed 256 equity positions with a combined reported value of $1.29B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 47.7% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were ABVX ($177.65M), PTGX ($91.63M), ROIV ($74.41M). By sector, the heaviest allocations are Health Care 79.4%, Financials 1.5%. Versus the prior quarter, allocation shifted toward Health Care (+0.9pp), Industrials (+0.5pp) and away from Other (-1.7pp).

Versus the prior quarter, ADAR1 Capital Management, LLC opened 33 new positions, trimmed 62 and fully exited 48, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 62% of names.

The largest new positions opened in Q4 2025 were IVA ($12.60M), TFX ($9.84M), CBIO ($7.19M).

Of the 48 positions fully exited versus the prior quarter, the largest were ETNB ($31.06M), MTSR ($7.98M), VRNA ($5.49M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • IVA INVENTIVA SA · $12.60M
  • TFX TELEFLEX INCORPORATED · $9.84M
  • CBIO CRESCENT BIOPHARMA INC. · $7.19M
  • BLTE BELITE BIO INC · $6.37M
  • DHR DANAHER CORP DEL · $5.86M
  • SPRB SPRUCE BIOSCIENCES INC · $5.05M
  • PALI PALISADE BIO INC · $4.71M
  • CRVS CORVUS PHARMACEUTICALS INC · $3.59M

Fully Exited (vs previous quarter)

  • ETNB 89BIO INC · prev qtr: $31.06M
  • MTSR METSERA INC · prev qtr: $7.98M
  • VRNA VERONA PHARMA PLC · prev qtr: $5.49M
  • XBI SPDR SERIES TRUST · prev qtr: $4.01M
  • MRUS MERUS N V · prev qtr: $3.14M
  • ASPC A SPAC III ACQUISITION CORP · prev qtr: $2.22M
  • KRRO KORRO BIO INC · prev qtr: $1.93M
  • WVE WAVE LIFE SCIENCES INC · prev qtr: $871.57K

Insider Transactions (Form 4)

Latest ADAR1 Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-11 Buy NextCure, Inc. 12,333 $5.10 SEC filing
2026-11-06 Buy NextCure, Inc. 3,662 $5.10 SEC filing
2026-11-05 Buy InMed Pharmaceuticals Inc. 2,640 $13.10 SEC filing
2026-11-05 Buy NextCure, Inc. 1,024 $5.10 SEC filing
2026-10-27 Buy NextCure, Inc. 3,553 $5.10 SEC filing
2026-10-26 Buy NextCure, Inc. 1,672 $5.03 SEC filing
2026-10-23 Buy InMed Pharmaceuticals Inc. 4 $1.32 SEC filing
2026-10-23 Buy NextCure, Inc. 5,626 $4.83 SEC filing

All insider transactions →

Fund Profile

ADAR1 Capital Management, LLC is an SEC-registered 13F filer based in Austin, TX, United States. As of Q2 2026 it reported 268 US equity positions with a combined value of $1.81B. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-130082 (status: Approved), registered 2024-04-25
  • Regulatory AUM (Form ADV): $1.68B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 268 positions · $1.81B reported value (Q2 2026)
  • Top 10 holdings = 34.2% of reported value
  • Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 6.5%
  • Average position size: $6.74M

Sector Tilt

  • Health Care 86.5%
  • Financials 2.6%
  • Industrials 0.4%
  • (classified holdings cover 90% of value)

Quarterly Activity

  • Q2 2026: 42 new, 99 added, 60 reduced, 69 exited
  • 67 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 79.4%
Financials 1.5%
Materials 0.0%
Other 18.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.32M $177.65M 13.79%
13.79%
Reduce
2 1.05M $91.63M 7.11%
7.11%
Add
3 3.43M $74.41M 5.78%
5.78%
Add
4 2.48M $63.07M 4.89%
4.89%
Add
5 546.53K $39.42M 3.06%
3.06%
Add
6 337.12K $38.80M 3.01%
3.01%
Hold
7 54.68K $37.29M 2.89%
2.89%
Add
8 540.17K $34.32M 2.66%
2.66%
Add
9 1.16M $32.27M 2.50%
2.50%
Reduce
10 5.42M $26.05M 2.02%
2.02%
Add
11 1.25M $21.99M 1.71%
1.71%
Add
12 541.62K $21.88M 1.70%
1.70%
Add
13 646.77K $17.57M 1.36%
1.36%
Add
14 509.68K $17.26M 1.34%
1.34%
Hold
15 8.06M $16.53M 1.28%
1.28%
Add
16 213.41K $16.32M 1.27%
1.27%
Add
17 233.91K $15.27M 1.19%
1.19%
Add
18 315.64K $14.56M 1.13%
1.13%
Add
19 309.37K $14.40M 1.12%
1.12%
Add
20 1.46M $13.92M 1.08%
1.08%
Reduce
21 1.39M $13.83M 1.07%
1.07%
Reduce
22 2.50M $13.73M 1.06%
1.06%
Reduce
23 59.68K $13.18M 1.02%
1.02%
Add
24 2.71M $12.60M 0.98%
0.98%
New
25 171.42K $12.49M 0.97%
0.97%
Add
26 135.59K $12.39M 0.96%
0.96%
Hold
27 147.13K $11.64M 0.90%
0.90%
Add
28 145.08K $11.56M 0.90%
0.90%
Add
29 890.36K $10.76M 0.83%
0.83%
Add
30 258.14K $10.72M 0.83%
0.83%
Add
31 80.63K $9.84M 0.76%
0.76%
New
32 3.90M $9.63M 0.75%
0.75%
Reduce
33 12.05K $9.30M 0.72%
0.72%
Reduce
34 203.97K $9.14M 0.71%
0.71%
Add
35 5.61M $8.69M 0.68%
0.68%
Add
36 1.41M $8.47M 0.66%
0.66%
Reduce
37 179.53K $7.44M 0.58%
0.58%
Add
38 235.97K $7.36M 0.57%
0.57%
Reduce
39 606.00K $7.19M 0.56%
0.56%
New
40 4.29M $6.98M 0.54%
0.54%
Add
41 39.84K $6.37M 0.49%
0.49%
New
42 13.72K $6.22M 0.48%
0.48%
Add
43 95.52K $6.19M 0.48%
0.48%
Add
44 1.24M $6.18M 0.48%
0.48%
Add
45 1.14M $6.06M 0.47%
0.47%
Add
46 456.72K $5.95M 0.46%
0.46%
Reduce
47 25.60K $5.86M 0.46%
0.46%
New
48 1.43M $5.73M 0.45%
0.45%
Add
49 51.35K $5.50M 0.43%
0.43%
Add
50 516.48K $5.49M 0.43%
0.43%
Hold

FAQ

What did ADAR1 Capital Management, LLC buy in 2025-Q4?

In its 2025-Q4 13F filing, ADAR1 Capital Management, LLC reported 256 equity positions worth $1.29B in aggregate; its largest disclosed positions were ABVX ($177.65M), PTGX ($91.63M), ROIV ($74.41M).

How large is ADAR1 Capital Management, LLC's portfolio?

ADAR1 Capital Management, LLC reported $1.29B of long equity holdings across 256 positions as of 2025-Q4. Top-10 holdings account for 47.7% of reported value.

What is ADAR1 Capital Management, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/adar1-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →